NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
01/06/2026
Back to search
Official data from USPTO
SILENCE THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
SILENCE THERAPEUTICS
ST13
US500000087479087Class
1, 5, 40, 42, 44
Filing
87479087
Registration
5553120
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
33
Latest update
01/27/2026
Trademark type
Word
Nice classes
1, 5, 40, 42, 44
Filing date
06/07/2017
Registration date
09/04/2018
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/06/2026
Last transaction
01/27/2026
Responsible office
United States Patent and Trademark Office
Status code
704
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
4
Owner type
99
Owner location
Berlin, DE
Examiner
I, DAVID C
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Silence Therapeutics GmbH
Representatives
Thad Chaloemtiarana Pattishall, McAuliffe, Newbury, Hilliard & Geraldson LLP
Technical classification
Nice Classes
Class 1Class 5Class 40Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicals used in industry and science; nucleic acid molecules for laboratory use; arrays of nucleic acid molecules for scientific and medical research; nucleic acid molecules mediating RNA interference for scientific and medical research
Class 5
Pharmaceutical and veterinary preparations for use in the treatment of rare diseasesiron overload disordersacromegalymetabolic diseasescardiovascular diseasealcohol use disorderdelayed graft function and acute kidney injury; Pharmaceutical and veterinary preparations containing a nucleic acid for use in the treatment of rare diseasesiron overload disordersacromegalymetabolic diseasescardiovascular diseasealcohol use disorderdelayed graft function and acute kidney injury; Pharmaceutical and veterinary preparations containing a nucleic acid for mediating RNA interference for use in the treatment of rare diseasesiron overload disordersacromegalymetabolic diseasescardiovascular diseasealcohol use disorderdelayed graft function and acute kidney injury; all goods mentioned before not for gynaecological pharmaceutical preparations; nucleic acid molecules for medical or veterinary use
Class 40
treatment of materials by laser beam; treatment of materialsthe addition of polymer additivesradio opacifiers and antimicrobial agents to render them ecogenicradiopaque or bacteriostatic; custom manufacture of nucleic acids for third parties; custom manufacture of lipids for third parties; custom manufacture of nucleic acid containing composition for third parties; custom manufacture of transformed biological cells to the specification of third parties
Class 42
Scientific and technological servicesresearch and design in the fields of RNA interference and delivery of pharmaceuticals; industrial analysis and research services in the fields of biological researchmolecular biologygenetics and microbiology; design and development of computer hardware and software; scientific and technological servicesresearch in the field of RNA interference and delivery of pharmaceuticals; industrial analysis and research services in the field of RNA interference and delivery of pharmaceuticals
Class 44
Medical Services; veterinary services; hygienic and beauty care for human beings and animals
Publications
History of USPTO decisions and trademark events.
33 publications found
8.PR
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED
01/06/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
12/23/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
12/17/2025
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
03/05/2025
ES8R
TEAS SECTION 8 RECEIVED
03/04/2025
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
09/04/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
09/04/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/19/2018
PUBO
PUBLISHED FOR OPPOSITION
06/19/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/30/2018
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
05/15/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/08/2018
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
05/08/2018
ISMR
WITHDRAWN FROM ISSUE - MANAGING ATTORNEY REQUEST
05/08/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/08/2018
PUBO
PUBLISHED FOR OPPOSITION
05/08/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/18/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/04/2018
XAEC
EXAMINER'S AMENDMENT ENTERED
04/04/2018
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
04/04/2018
GNEA
EXAMINERS AMENDMENT E-MAILED
04/04/2018
CNEA
EXAMINERS AMENDMENT -WRITTEN
04/04/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/02/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/02/2018
ALIE
ASSIGNED TO LIE
03/28/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/14/2018
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/14/2017
GNRT
NON-FINAL ACTION E-MAILED
09/14/2017
CNRT
NON-FINAL ACTION WRITTEN
09/14/2017
DOCK
ASSIGNED TO EXAMINER
09/07/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/14/2017
NWAP
NEW APPLICATION ENTERED
06/10/2017
Continuous trademark protection
Get notified about every new filing that threatens SILENCE THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.